Matheus Montecasciano
Matheus Montecasciano
Professional experience
Matheus Montecasciano has wide experience in the practice of health regulatory law, representing clients in administrative litigation before the National Health Surveillance Agency (Anvisa) and other health authorities, as well as in public tenders and contracts promoted by the public administration.
He counsels national and international clients from many different sectors, with special focus on companies from the pharmaceutical, food, medical devices, and cosmetics industries.
Education
- Post-graduate diploma in Economic Law from Fundação Getulio Vargas (FGV) – 2020;
- Bachelor of Laws from the Pontifical Catholic University of São Paulo (PUC-SP) – 2013.
Publications
- Getting the Deal Through – Life Sciences. “Brazil Chapter”. London: Pharma & Medical Device Regulation, 2022 (co-author);
- Getting the Deal Through – Life Sciences. “Brazil Chapter”. London: Pharma & Medical Device Regulation, 2021 (co-author).
Additional Activities
- Member of Sindusfarma.
Recognitions
related content
-
Client Alert
Brazilian Telehealth act Comes Into Force
On December 28, 2022, Law No. 14,510/2022 (Telehealth Act), which authorizes the practice of Telehealth throughout the Brazilian territory, came into force. After lengthy discussion and approval by Congress, the President sanctioned the final wording of the Bill of Law 1,998/2020 without vetoes.
02/01/2023
-
Client Alert
Anvisa opens a Public Consultation to propose authorization for the skinny label practice
As previously informed in the client alert sent on December 23, Anvisa opened a Public Consultation (PC 1,137/2022) to amend Resolution-RDC 47/2009 - which sets forth rules for the elaboration, harmonization, updating, publication, and availability of labels of medicines for patients and health care professionals.
29/12/2022
-
Client Alert
Anvisa’s Board of Directors approved the opening of a Public Consultation to propose authorization for the skinny label practice
At the last meeting of 2022, held on December 22, Anvisa’s Board of Directors approved a Public Consultation to amend Resolution-RDC 47/2009 - which sets forth rules for the elaboration, harmonization, updating, publication, and availability of labels of medicines for patients and health care professionals.
23/12/2022